ImmunoGenesis

The company translates discoveries from academic tumor immunology into drugs intended to treat the majority of patients with cold cancers refractory to currently available immunotherapy.

BostonGene and ImmunoGenesis partner to advance IMGS-001, a dual-targeting immune checkpoint inhibitor blocking PD-L1 and PD-L2. The collaboration aims to accelerate clinical development of ImmunoGenesis’s lead program, currently in a phase 1a/b trial evaluating safety and efficacy. BostonGene’s AI-driven tumor and immune biology model supports the effort.

Apr 2026bostongene.comNews article

ImmunoGenesis secures a **$10.8 million grant** from the **Cancer Prevention & Research Institute of Texas (CPRIT)** to advance **IMGS-001**, its lead immunotherapy targeting **PD-L1 and PD-L2**. The funding supports clinical trials for patients with **immune-excluded solid tumors**, addressing a high unmet medical need. IMGS-001 is a cytotoxic immune checkpoint inhibitor in development for treating difficult-to-treat cancers.

Dec 2025immunogenesis.comNews article

ImmunoGenesis presents Phase 1a/1b trial updates for its immunotherapy candidate **IMGS-001** at the **2025 ASCO Annual Meeting**. The company’s first-in-human study evaluates safety and efficacy in oncology patients. The presentation includes a **Trial in Progress** poster highlighting early clinical findings.

May 2025immunogenesis.comNews article

ImmunoGenesis expands its Phase 1a/b trial of the experimental therapy **IMGS-001** to **Ochsner MD Anderson Cancer Center**, broadening access for patients with advanced solid tumors. The company develops immune-based therapies, while **Cancer Focus Fund**—a joint venture with **MD Anderson**—provides funding and clinical support for the trial. IMGS-001 remains ImmunoGenesis’ lead candidate in this clinical development phase.

May 2025immunogenesis.comNews article